Helicobacter pylori: A historical perspective 1983-2003

New Zealand Medical Journal

Volumn 117, Issue 1194, 2004, Pages

  Fraser, Alan ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BISMOL; BISMUTH CITRATE; BISMUTH SALICYLATE; CLARITHROMYCIN; HISTAMINE H2 RECEPTOR ANTAGONIST; METRONIDAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROTON PUMP INHIBITOR; TETRACYCLINE; UVOMORULIN; ORGANOMETALLIC COMPOUND;

ABDOMINAL PAIN; ANTIBIOTIC RESISTANCE; ATROPHIC GASTRITIS; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG TOLERABILITY; DUODENUM ULCER; ETHNIC DIFFERENCE; GASTRITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL INFECTION; GEOGRAPHIC DISTRIBUTION; HELICOBACTER PYLORI; HISTORY OF MEDICINE; HUMAN; INFECTION CONTROL; LONG TERM CARE; MEDICAL RESEARCH; NAUSEA; PATIENT COMPLIANCE; REVIEW; RISK ASSESSMENT; SCANNING ELECTRON MICROSCOPY; SIDE EFFECT; STOMACH ACID SECRETION; STOMACH CANCER; TREATMENT OUTCOME; ARTICLE; CHEMICALLY INDUCED DISORDER; COMORBIDITY; DRUG COMBINATION; HELICOBACTER INFECTION; HISTORY; ISOLATION AND PURIFICATION; MICROBIOLOGY; PEPTIC ULCER; PREVALENCE; REFLUX ESOPHAGITIS; STOMACH TUMOR;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COMORBIDITY; DRUG THERAPY, COMBINATION; ESOPHAGITIS, PEPTIC; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HISTORY, 20TH CENTURY; HUMANS; METRONIDAZOLE; ORGANOMETALLIC COMPOUNDS; PEPTIC ULCER; PREVALENCE; STOMACH NEOPLASMS; TETRACYCLINE;

EID: 3042633412     PISSN: 11758716     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet. 1983;i:1273-5.
2. Morris A, Nicholson G. Ingestion of Campylobacter pyloridis causes gastritis and raised gastric pH. Am J Gastroenterol. 1987;82:192-9.
3. Morris A. Ali MR, Nicholson G, et al. Long-term follow-up of voluntary ingestion of Helicobacter pylori. Ann Int Med. 1991;114:662-3.
4. Fraser AG, Moore L, Ali MR, et al. An audit of low dose triple therapy for eradication of Helicobacter pylori. N Z Med J. 1996;109;290-2.
5. Fraser AG, Moore L, Berry S, Arroll B. Eradication treatment for Helicobacter pylori in general practice. N Z Med J 1996;109:422-4.
6. Fraser AG, Moore L, Hackett M, Hollis B. Helicobacter pylori treatment and antibiotic susceptibility: results of a 5-year audit. Aust N Z J Med. 1999;29:512-6.
7. Lane MR, Lee SP. Recurrence of duodenal ulcer after medical treatment. Lancet. 1988; i:1147-9.
8. Fraser AG, Schreuder V, Chua L, Moore L. Follow-up after successful eradication of H. pylori-symptoms and re-infection. J Gastro Hepatol.1998;13:555-9.
9. Thomsen LL, Gavin JB, Tasman-Jones C. Relation of Helicobacter pylori to human gastric mucosa in chronic gastritis of the antrum. Gut. 1990;31:1230-6.
10. Morris A, Nicholson G, Lloyd G, et al. Seroepidemiology of Campylobacter pyloridis. N Z Med J. 1986;99:657-9.
11. Beg F, Oldmeadow M, Morris A, Nicholson G. Campylobacter pylori infection in patients undergoing endoscopy in Fiji. N Z Med J. 1998;101:140-1.
12. Nicholson G, Morris A, Miller M, Akau'ola H. Campylobacter pylori infection in patients undergoing endoscopy in Tonga. N Z Med J. 1988;101:124.
13. Malaty HM, El-Kasabany A, Graham DY, et al. Age at acquisition of Helicobacter pylori infection: a follow-up study from infancy to adulthood. Lancet. 2002;359:931-5.
14. Langman M. Commentary: peptic ulcer, Susser and Stein and the cohort phenomenon. Int J Epidemiol. 2002;31:27-8.
15. Fraser AG, Scragg R, Metcalf P, et al. Prevalence of Helicobacter pylori in different ethnic groups in New Zealand children and adults. Aust N Z J Med 1996; 26:646-51.
16. Collett JA, Burt MJ, Frampton CM, et al. Seroprevalence of Helicobacter pylori in the adult population of Christchurch: risk factors and relationship to dyspeptic symptoms and iron studies. NZ Med J 1999;112:292-5.
17. Fawcett JP, Shaw JP, Cockburn M, et al. Seroprevalence of Helicobacter pylori in a birth cohort of 21-year old New Zealanders. Eur J Gastro Hepatol. 1996;4:365-70.
18. Schmid J, Fraser AG, Hollis B, O'Toole P. Ethnic tropism of DNA fingerprints of Helicobacter pylori. Infection and Immunity. 1997;65:3708-12.
19. Falush D, Wirth T, Linz B, et al. Traces of human migrations in Helicobacter pylori populations. Science. 2003; 299:1582-5.
20. Garrigan K, McIntosh C, Fraser AG. Bleeding peptic ulcers: audit of eradication for H pylori. N Z Med J 1999;112:178-80.
21. Laine L, Schoenfeld P, Fennerty MB. Therapy for Helicobacter pylori in non-ulcer dyspepsia. A meta-analysis of randomised trials. Ann Intern Med. 2001;134:361-9.
22. Moayyedi P, Soo S, Deeks J, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2004;(1):CD002301.
23. Lassen AT, Pedersen FM, Bytzer P, et al. Helicobacter pylori test-and-eradicate vs. prompt endoscopy for dyspepsia patients in primary care. Lancet. 2000;356:455-60.
24. McColl KEL, Murray LS, Gillen D, et al. Randomised trial of endoscopy with testing for Helicobacter pylori compared with non-invasive H pylori testing alone in the management of dyspepsia. BMJ. 2002; 324: 999-1002.
25. Fraser AG, Williamsom S, Lane MR, Hollis B. Nurse-led dyspepsia clinic using the urea breath test for Helicobacter pylori. N Z Med J. 2003;116(1176). URL: http://www.nzma.org.nz/journal/116-1176/479/
26. Fraser AG, McIntosh C, Berry S, Moore L. Can the urea breath test for H.pylori replace endoscopy for the assessment of dyspepsia in primary care? N Z Med J. 1998;111:11-4.
27. Scragg RK, Fraser A, Metcalf PA. Helicobacter pylori seropositivity and cardiovascular risk factors in a multicultural workforce. J Epidemiol Community Health. 1996;50:578-9.
28. Fraser AG, Scragg RK, Cox B, Jackson RT. Helicobacter pylori, Chlamydia pneumoniae and myocardial infarction. Int Med J. 2003;33:267-72.
29. Moayyedi P, Bardhan C, Young L, et al. Helicobacter pylori eradication does not exacerbate reflux symptoms in gastro-oesophageal disease. Gastroenterology. 2001;121;1120.
30. Schwizer W, Thumshirn M, Dent J, et al. Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomized controlled trial. Lancet. 2001;357:1738-42.
31. Schenk BE, Kuipers EJ, Nelis GF, et al. Effect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy. Gut. 2000;46:615-21.
32. Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut. 2001;49:347-53.
33. Fraser AG, Peng SL, Jass JR. Intestinal metaplasia subtypes and Helicobacter pylori infection: a comparison of ethnic groups in New Zealand. J Gastroenterol Hepatol. 1998;13:560-5.
34. Sung JJ, Lin SR, Ching JY, et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology. 2000;119:7-14.
35. Pharoah PD, Guilford P, Caldas C. International Gastric Cancer Linkage Consortium. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology. 2001;121:1348-53.
36. Parsonnet J, Harris RA, Hack HM, Owens DK. Should we treat H. pylori infection to prevent gastric cancer? Gastroenterology. 1997;112:1044-5.
37. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet. 2002;359:14-22.
38. Chan FK, To KF, Wu JC, et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet. 2002; 359:9-13.